Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox injection method comparison in chronic migraine
IRCT20180203038600N1Phase 2Completed
- Sponsor
- Rafsanjan University of Medical Sciences
- Start
- Feb 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of botulinum toxin type A in chronic migraine (2 arms), sponsored by Rafsanjan University of Medical Sciences. Primary endpoints: Decrease in frequency of migrainous headache, Decrease in severity of migrainous headache and 1 more. Started Feb 2018; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
chronic migraine
Beyond the preview
Go deeper on IRCT20180203038600N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180203038600N1.